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Summary 
Automated quantification of abnormalities associated with COVID-19 from chest CT could help clinicians 
evaluate the disease and assess its severity and progression. This study proposes measures of disease 
severity and a deep learning and deep reinforcement-based method to compute them. 
Key Points 
• The method computes percentage of opacity (PO) and lung severity score (LSS) by segmenting 
three-dimensional abnormalities associated with COVID-19, namely ground glass opacities and 
consolidations. The PO and LSS quantify the extent of lung involvement and the distribution of 
involvement across lobes, respectively. 
• Given that high opacity abnormalities (ie consolidations and sub-solid regions) were shown to 
correlate with severe symptoms, this study introduces two complementary severity measures 
percentage of high opacity (PHO) and lung high opacity score (LHOS). They quantify the extent 
of high opacity abnormalities and their distribution of involvement across lobes, respectively.  
• The combined severity measures of (PO, PHO) and (LSS, LHOS) quantify the extent of overall 
COVID-19 abnormalities and the presence of high opacities, global and lobe-wise, respectively.  
• The performance of the method in estimating PO, LSS, PHO, and LHOS is evaluated on a 
database of 100 COVID-19 and 100 controls CT scans from multiple institutions from Canada, 
Europe, and US. Ground truth was established by computing the same measures from manual 
annotations of the lesions, lungs, and lobes. The Pearson correlation coefficient between 
method prediction and ground truth was calculated as 0.95 for PO (P < .001), 0.98 for PHO(P < 
.001), 0.96 for LSS (P < .001), 0.96 for LHOS  (P < .001). 
List of Abbreviations 
COVID-19 = Coronavirus Disease 2019, ILD = interstitial lung diseases, LHOS = lung high opacity score, 
LSS = lung severity score, PHO = percentage of high opacity, PO = percentage of opacity, ROI = region of 
interest, RT-PCR = reverse transcription polymerase chain reaction, 3D = three-dimensional 
 
  
ABSTRACT  
Purpose 
To present a method that automatically segments and quantifies abnormal CT patterns commonly 
present in coronavirus disease 2019 (COVID-19), namely ground glass opacities and consolidations.  
Materials and Methods 
In this retrospective study, the proposed method takes as input a non-contrasted chest CT and segments 
the lesions, lungs, and lobes in three dimensions, based on a dataset of 9749 chest CT volumes. The 
method outputs two combined measures of the severity of lung and lobe involvement, quantifying both 
the extent of COVID-19 abnormalities and presence of high opacities, based on deep learning and deep 
reinforcement learning. The first measure of (PO, PHO) is global, while the second of (LSS, LHOS) is lobe-
wise. Evaluation of the algorithm is reported on CTs of 200 participants (100 COVID-19 confirmed 
patients and 100 healthy controls) from institutions from Canada, Europe and the United States 
collected between 2002-Present (April, 2020). Ground truth is established by manual annotations of 
lesions, lungs, and lobes. Correlation and regression analyses were performed to compare the prediction 
to the ground truth. 
Results 
Pearson correlation coefficient between method prediction and ground truth for COVID-19 cases was 
calculated as 0.92 for PO (P < .001), 0.97 for PHO(P < .001), 0.91 for LSS (P < .001), 0.90 for LHOS  (P < 
.001). 98 of 100 healthy controls had a predicted PO of less than 1%, 2 had between 1-2%. Automated 
processing time to compute the severity scores was 10 seconds per case compared to 30 minutes 
required for manual annotations. 
Conclusion 
A new method segments regions of CT abnormalities associated with COVID-19 and computes (PO, 
PHO), as well as (LSS, LHOS) severity scores. 
 
 
 
  
INTRODUCTION  
 Coronavirus disease (COVID-19) is an infectious disease affecting more than 2 400 000 
individuals worldwide as of April 20, 2020 (1). The disease is caused by the severe-acute respiratory 
symptom coronavirus 2 (SARS-Cov2) and has a high case fatality rate of up to 4% (2) with more than 170 
000 deaths reported currently around the globe.  Due to a high reproduction number and infectious 
nature of the disease, tools for rapid testing and evaluation are vital to track and mitigate the spread.  
 COVID-19 infection is confirmed by a reverse transcription polymerase chain reaction (RT-PCR) 
(3). However, the sensitivity of this test may be as low as 60-70% (4) and can result in false negatives 
within first few days of infection. The role of CT for diagnosis is currently being debated, however two 
preliminary studies (5,6) showed that chest CT imaging of the lung provides improved sensitivity when 
compared to RT-PCR for patients suspected to have COVID-19. These studies show that non-contrast 
chest CT has been useful to detect, quantify severity, and assess progression of the disease. The primary 
features observed on a lung affected by COVID-19 are peripheral focal or multi-focal ground glass 
opacities, consolidation, and crazy-paving patterns.  
 In another study, CT scans were evaluated from patients that tested positive for COVID-19 
across 552 hospitals in China (7). They found that 84.4% of patients exhibiting mild symptoms showed 
CT changes, whereas 94.6% of patients exhibiting severe symptoms showed CT changes. In a study of 
121 patients, Bernheim et al showed that CT changes correlated with disease severity, with increasing 
lung involvement and abnormalities as the disease progressed (8). A recent radiologist performance 
study also points to preliminary evidence that radiologists can discriminate COVID-19 from other types 
of pneumonia (9). The study showed that seven United States and Chinese radiologists were able to 
identify COVID-19 from other types of viral pneumonia with a median sensitivity of 73% and a median 
specificity of 93%(9). The studies so far have been performed on patients either suspected or confirmed 
to be tested positive of COVID-19, therefore it is too early to state that CT can be used as an effective 
diagnostic or screening tool for evaluation of COVID-19 in general population. However, most patients 
with COVID-19 do seem to exhibit CT abnormalities and the extent of these changes seem to correlate 
with disease severity. Recently, the Fleischner society provided recommendations for use of chest 
imaging in evaluation of COVID-19 in regions with resource constraints especially for patients with 
worsening respiratory status, suspected false negative PCR, and more severe infection. Elsewhere, they 
indicated that chest imaging can be used to establish a baseline for moderate to severe cases (10). As a 
result, CT imaging is being adapted as a tool to evaluate COVID-19 in emergency rooms across the world, 
where other resources for testing are scarce. 
 We propose an automated system that can quantify the abnormalities most often seen in 
COVID-19 (ie ground glass opacities and consolidations). The system outputs regions of abnormality 
demarcated in a three-dimensional CT scan and output two combined severity measures of the disease: 
(a) (percentage of opacity, percentage of high opacity) or (PO, PHO) and (b) (lung severity score, lung 
high opacity score) or (LSS, LHOS). The first measure (PO,PHO) indicates the overall disease spread 
relative to the volume of the lungs, while the second measure (LSS, LHOS) is  a cumulative measure of 
the extent of involvement for each lung lobe (Figure 1). Opacities here include GGO, consolidation, and 
crazy-paving patterns which are all commonly observed in COVID-19. Given that higher opacity 
abnormalities such as consolidation were shown to correlate with severe symptoms, the measures cover 
both the extent of disease and the presence of high opacities (7,11).  In this study, we use the term high 
opacity to mean consolidation of sub-solid regions of high attenuation. We use this term since these 
regions were determined using an empirical threshold. The ability to determine the extent of 
abnormalities and quantify the presence of high opacities provides valuable insight for prognosis 
prediction, risk prioritization, and therapy response (12).     
MATERIALS AND METHODS 
All the authors have either been employed or partially supported by Siemens Healthineers. 
Datasets and Annotation.  
The datasets were de-identified and retrospectively collected from multiple centers in USA, Canada, and 
Europe, between 2002 to present (April, 2020) with the respective data usage being approved by 
respective ethics committees. A subset of the datasets are from NLST(13) and COPDgene(14).  Non-
contrasted chest CT datasets that completely show lungs in their field of view were used to train two 
models: one for lung and lobe segmentation and another for abnormality segmentation.  Complete 
details of the datasets are provided in Tables 1 and 2, including age and sex distribution, CT scanner 
manufacturer, slice thickness, and kernel type.  
A total of 9749 CT volumes were used in the study. A total of 200 volumes were reserved for testing, and 
the remaining were used for lung and lesion segmentation training and model selection. A total of 901 
volumes were used for training the abnormality segmentation model. Due to limited availability of 
COVID-19 data, we determined three groups of data that are useful for training the abnormality model: 
COVID-19 datasets (n = 431), pneumonia datasets (n = 174) and other interstitial lung diseases (ILDs, n = 
274).  Note that 575 datasets were common to the lung segmentation and lesion segmentation training 
sets. The distribution of the datasets for each task is visualized in Figure 2. Annotation details for the 
two tasks are presented in Appendix E1 (supplement).  A separate test set of 100 control volumes and 
100 COVID-19 positive volumes were used to evaluate lung and lobe segmentation as well as 
abnormality segmentation. The control group consisted of volumes without CT abnormalities that were 
randomly sampled and visually inspected by a radiologist. There were 110 COVID-19 positive cases that 
were randomly selected from two European and two institutions from the United States. Of these, 10 
cases were excluded for having very low percentage of abnormalities based on ground truth 
annotations.  
Lung and Lobe Segmentation 
The algorithm generates lung and lobe segmentation mask on a given CT data set. First, multi-scale deep 
reinforcement learning (15) is used to robustly detect anatomical landmarks in a CT volume. The carina 
bifurcation is used to identify the lung region of interest (ROI). When the lung ROI is not detected by the 
system, the sternum tip is used as a landmark. The size and the relative location of the lung ROI to the 
landmark are specified according to annotated lung datasets. Next, the lung ROI image is resampled to a 
2 mm isotropic volume and fed into a Deep Image-to-Image Network (DI2IN) (16) to generate the lung 
segmentation. Finally, the ROI segmentation mask is remapped to have the same dimension and the 
resolution as the input data. The DI2IN has been first trained on CT scans from a large group of patients 
with various diseases (miscellaneous in Table 1), then fine-tuned with scans with abnormal patterns 
including ( ILDs, pneumonia, and COVID-19 in Table1), to improve the robustness of the lung 
segmentation over the infected areas. 
COVID-19 Related Abnormality Segmentation 
We formulated the segmentation of the COVID-19 related abnormality patterns as a semantic 
segmentation problem involving binary classes. A DenseUNet (17) with anisotropic kernels is trained to 
transfer a three-dimensional (3D) chest CT volume to a semantic segmentation mask of the same size. 
We use a single label to define all voxels within the lungs that fully or partially contain ground glass 
opacity or consolidations as the positive voxels (see Annotation Details in Appendix E1). The rest of the 
image areas within the lungs and the entire area outside the lungs are defined as negative. The network 
is trained as an end-to-end segmentation system. The 3D output segmentation is filtered by the lung 
segmentation as described above. The technical details of the network architecture and the training 
strategy are summarized in Appendix E1 (supplement).  
COVID-19 Severity Measures 
The severity of airspace abnormalities in each subject is measured by the combined metrics (PO, PHO) 
and (LSS, LHOS) as defined below. 
Percentage of Opacity (PO): The PO is calculated as the total percent volume of the lung parenchyma 
that is affected by disease: 
𝑃𝑂 = 100 ×
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑎𝑏𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑡𝑖𝑒𝑠
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑙𝑢𝑛𝑔 𝑚𝑎𝑠𝑘
 
Percentage of High Opacity (PHO): The PHO is calculated as the total percent volume of the lung 
parenchyma that is affected by severe disease (ie high opacity regions including consolidation). The 
high-opacity regions were identified using a threshold on -200 HU from the abnormality segmentation:  
𝑃𝐻𝑂 = 100 ×
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 ℎ𝑖𝑔ℎ 𝑜𝑝𝑎𝑐𝑖𝑡𝑦 𝑟𝑒𝑔𝑖𝑜𝑛 
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑙𝑢𝑛𝑔 𝑚𝑎𝑠𝑘 
 
 
Lung Severity Score (LSS): The LSS is computed to measure the extent of lung involvement across each 
lobe as described by Bernheim et al (8). For each lobe, the percentage of affected lobe is calculated and 
scored between 0-4: (0) lobe is not affected; (1) 1-25% of the lobe is affected; (2) 25-50% of the lobe is 
affected; (3) 50-75% of the lobe is affected; and (4) 75-100% of the lobe is affected. 
The scores for each of the five lobes are summed to calculate the total LSS, resulting in a total score 
range from 0-20. A 0 indicates that none of the lobes are involved and 20 indicates that all five lobes are 
severely affected.   
Lung High Opacity Score (LHOS):  The LHOS is computed to measure the extent of abnormalities with 
severe disease. For each lobe, the percentage of high opacity is calculated and scored between 0-4: (0) 
lobe is not affected, or abnormalities do not have any consolidation; (1) 1-25% of the lobe has high 
opacity abnormalities; (2) 25-50% of the lobe has high opacity abnormalities; (3)  50-75% of the lobe has 
high opacity abnormalities; and (4) 75-100% of the lobe has high opacity abnormalities. 
The scores for each of the five lobes are summed to calculate the total LHOS, resulting in a total score 
range from 0-20. A 0 indicates that none of the lobes have a high opacity abnormality and 20 indicates 
that all five lobes are severely affected by high opacity consolidations.  
Statistical Analysis 
The aim of the study is to show that abnormalities associated with COVID-19, namely GGO and 
consolidation, are segmented in a given CT scan, and to also demonstrate that there are no false 
positive segmentations when there are no abnormalities. In order to do this, we show that ground truth 
matches the predicted scores of severity using the following statistical tests. 
Chi-squared contingency test 
We compute the chi-squared contingency test (18) between ground truth and predicted scores. For LSS 
and LHOS, the frequencies are computed for each value from 0-20 in order to calculate the test. For PO 
and PHO the frequencies are estimated based on clinically relevant (8) bins, 0-1%, 1-25%, 25-50%, 50-
75%, 75-100%. 
Correlation 
We compute two types of correlations: Pearson’s coefficient and Kendall’s Tau using python’s scipy 
package (19,20). Pearson’s coefficient demonstrates the linear association between ground truth and 
predicted values. The Kendall’s Tau measures the ordinal relationship between the ground truth and 
predicted metrics, i.e., it measures the agreement between the rankings of the two measures. We 
compute the correlations for all the subjects, and for COVID-19 positive subjects alone. 
Linear relationship 
In order to further evaluate the linear relationship between the ground truth and predicted metrics, we 
compute the linear regression estimates for metrics which have continuous values (PO and PHO), as 
follows:   
𝑚𝑒𝑡𝑟𝑖𝑐𝑔𝑡 = 𝛽0 + 𝛽1𝑚𝑒𝑡𝑟𝑖𝑐𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑  
We report the following: 
• ?̂?0, the estimate of the intercept of the linear regression, along with the confidence interval. 
• ?̂?1, the estimate of the slope for the linear regression, along with the confidence interval. 
• Coefficient of determination or R-squared value. 
• Mean squared error of the metric from the regression line. 
RESULTS  
Training of Lung and Lobe Segmentation 
We used 8792 chest CT volumes for training the 3D segmentation of lung and lobes. The DI2IN was first 
trained on a data set from 8087 patients (8006 for training and 81 for validation) without the prevalence 
of viral pneumonia, then it was fine-tuned on another data set from 1136 patients (1076 for training and 
60 for validation) with abnormality patterns including ground glass opacities, consolidation, effusions, 
masses, and others to improve the robustness of the lung and lobe segmentation over the infected 
areas. The DI2IN was finally tested on a data set from 200 patients, consisting of 100 COVID-19 and 100 
controls (13). The sample size and the data partition of the COVID-19 positive patients are determined 
by balancing the patients from the US and Europe (see Table 1).  
Training of Abnormality Segmentation 
For the training of abnormality segmentation, we used a combination of COVID19, viral pneumonia, and 
other ILD datasets, totaling 901 CT scans (431 COVID-19, 174 viral pneumonia, and 296 ILD).  Atypical 
pneumonia datasets including SARS, MERS, and other viral pneumonia have similar CT abnormalities as 
COVID-19 (21) and are used as reasonable proxies to complement the COVID-19 training dataset 
together with CT datasets that include other ILDs that present with GGO and consolidation. These 
datasets were used in the training dataset to learn the patterns relevant in COVID-19. For the testing 
set, both the initial annotation and final review was done by a board-certified radiologist. For testing, we 
used the same 200 datasets as for the lung and lobe segmentation, which includes 100 COVID-19 and 
100 controls (13). 
Computation of Combined Measures of Disease Severity 
From the predicted abnormality segmentation, we compute the two proposed combined measures of 
disease severity: (a) (PO, PHO) and (b) (LSS, LHOS) for the 200-test data set that consisted of 100 COVID-
19 and 100 controls. We show that abnormalities of GGO and consolidation are segmented and 
quantified accurately in cases with COVID-19. We also show that there are no false positives segmented 
in most subjects with no pathology. A chi-squared contingency test between ground truth and predicted 
metrics shows that there is no significant difference between ground truth and predicted metrics for 
clinically relevant binning of the measures (see Table 3). 98% of healthy controls have a predicted PO 
less than 1%. 2 have some PO detected between 1-2%. We also computed linear and ordinal correlations 
for the four metrics. The Pearson coefficients for COVID-19 positive  cases  are 0.92 for PO (P < .001); 
0.97 for PHO (P < .001); 0.91 for LSS (P < .001); and 0.90 for LHOS (P < .001).  The Kendall Tau is 0.77 for 
PO (P < .001); 0.86 for PHO (P < .001); 0.83 for LSS (P < .001); and 0.83 for LHOS (P < .001). All 
correlations are statistically significant, demonstrating the system’s ability to predict lung severity 
measures in COVID-19 datasets. In addition to correlation, we also present estimates of the linearity of 
the relationship between ground truth and predicted metrics for PO and PHO for COVID-19 positive 
cases, as shown in Table 4. The intercept is close to 0, showing that there is no bias. The slopes are 0.839 
and 0.805, indicating a slight over estimation in the predicted metrics. The mean error between ground 
truth and predicted PO and PHO are 3.5% and 1.9% respectively. 
Figure 4 shows the scatter plot between ground truth and predicted metrics PO, PHO, LSS, and LHOS. 
Figure 5 shows the combined measures of (PO, PHO) as well as (LSS, LHOS) in two-dimensional plots. The 
diagonal in Figure 5(a) indicates that PO is equal to PHO. A subject’s marker falling on the diagonal 
would indicate that 100% of the abnormalities present on their lung CT are high opacity or consolidation. 
Note that all the markers for abnormalities greater than 0 fall below the line, indicating various levels of 
consolidation present. The closer a subject’s marker is to the diagonal, the more consolidation there is in 
their lungs. In Figure 5(b), the diagonal indicates that LSS is equal to LHOS. A marker on the diagonal 
here indicates that all the lobes that are involved have high opacity. When a patient’s marker falls below 
the diagonal, it means that either some lobes do not have high opacities or that they have less extent of 
high opacities.  
Figure 6 shows the qualitative results for COVID-19 positive cases along with their scores. Figure 6 (a) 
shows six cases where our algorithm segments the abnormality regions accurately. For example, the 
upper left corner case resulted in a (PO, PHO) = (55.9%, 7.6%). That means that 55.9% of the lung 
volume is affected by disease and 7.6% of the lung volume has high consolidation abnormalities. Figure 
6 (b) shows one example of abnormality segmentation (left) along with high opacity regions identified 
through thresholding (right). Figure 6 (c) shows two cases which were identified as outliers due to their 
PO score differing by more than 20% from the ground truth. The algorithm misses fainter areas of 
opacity (left) and tends to over segment into normal areas between the abnormal opacities (right).  
DISCUSSION 
In this work we proposed a method to automatically quantify regions with ground glass opacity and 
consolidation in chest CT scans using deep learning algorithms. The abnormalities segmented by our 
system are the most common chest CT findings in COVID-19. The system outputs the 3D contours of the 
CT abnormalities and computes two combined severity measures of(PO, PHO) and (LSS, LHOS). 
Clinical value of our system 
Automated characterization of disease can be extremely useful to facilitate rapid response in assessing 
the extent of lung infection and progression of the disease in patients exhibiting symptoms of COVID-19. 
Evaluation of a chest CT can be used to answer several questions in a clinical setting such as triage of a 
patient, diagnosis, assessment of severity and progression, and response to therapy. Recently, lung 
severity measures have been proposed for COVID-19 that demonstrate correlation to disease severity 
and progression (8,22–25). Manual calculation of these scores produces a two-fold problem: either the 
affected regions are annotated precisely, which is a time-consuming process, or the affected regions are 
assessed subjectively, which translates into low reproducibility of the assessment. A precise automated 
measurement of lung severity scores will address both the speed and reproducibility problems. In 
addition to quantitative outputs, the abnormality segmentation produced by the system can also be 
used for visual interpretation and inspection. 
The automatic computation of (PO, PHO) as well as (LSS, LHOS) as provided by our system would be 
useful in several clinical scenarios: 
Severity assessment.— An objective quantitative measure of severity is provided by (PO, PHO) and (LSS, 
LHOS) scores. This measure can be used in triage, to prioritize patients requiring hospital or intensive 
care unit admittance, and to assess the prognosis of a patient.  
Progression assessment.— In several instances, the patient might be imaged multiple times to assess 
disease progression or to assess response to drugs. In order to make these decisions, an objective metric 
or a score that can assess the extent of disease is vital. The (PO, PHO) and (LSS, LHOS) scores can be 
useful when evaluating a patient’s lung status over time. Such a tool could also be used in scientific 
research studies that are documenting the temporal radiological change of COVID-19 pneumonia and 
clinical trials studying drug responses. 
Early detection.— Although the evidence is preliminary, the system could be used as an effective tool in 
conjunction with RT-PCR tests to increase overall sensitivity of COVID-19 detection, especially in 
scenarios where there are limited resources and a crunch for time. 
An automated system that can perform this disease severity assessment can be of great use to hospitals 
that have a shortage of manpower combined with a high-volume of patients during the outbreak (12). 
Technical Contributions 
To our knowledge this is one of the first systems to provide an automatic, efficient, and detailed 
evaluation of tomographic CT patterns associated with COVID-19.  We also believe that this is the first 
system to propose and show how to automatically compute severity measures such as (PO, PHO) and 
(LSS, LHOS) that characterize not only the extent of disease in the lungs, but also the extent of high 
opacity abnormalities, both globally and lobe-wise. This performance is facilitated by the experience of a 
multidisciplinary team of clinicians, machine learning experts, and engineers, whose combined clinical 
and technical knowledge helped to solve robust landmark detection in chest CT, 3D lung and lobe 
segmentation, and 3D segmentation of abnormalities associated with COVID-19.   
Limitations and Future Work 
The system was trained with specific abnormalities that were relevant to COVID-19 such as ground glass 
capacities and consolidations. Presence of other abnormalities in or around the lung such as pleural 
effusion could produce challenges to the algorithm. In the future, the system will be trained 
comprehensively to account for abnormalities other than GGO and consolidation. The algorithm will be 
improved using more training data in boundary conditions, which cause under segmentation with faint 
regions and over segmentation with highly abnormal regions as seen in Figure 6 (c). The system 
produces a quantification of abnormalities in a lung CT scan only. While we evaluate this quantification  
in COVID-19 and healthy cases, we do not evaluate it in other lung diseases such as other viral 
pneumonias or ILDs.   It is difficult to ascertain the differences between diseases and diagnosis capability 
based on this information alone. In the future, we will evaluate the feasibility of distinguishing COVID-19 
from other types of pneumonias and ILDs. We will conduct studies to correlate the imaging findings 
computed in this work to clinical factors and outcomes. A similar study can be performed with X-ray 
chest images as well, which will be a part of our future investigations. These additional studies can 
provide a comprehensive toolbox for clinicians to diagnose and treat COVID-19. 
 
Disclaimer: The concepts and information presented in this paper are based on research results that are 
not commercially available 
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TABLES 
 
Table 1. Properties of Training and Testing Data used for Lung and Lobe Segmentation 
 
Parameter Training dataset Testing Dataset 
Dataset composition   
   Total 9223 200 
   COVID-19 148 100 
   Viral Pneumonia 161 0 
   Interstitial Lung Disease 827 0 
   Miscellaneous 8087 0 
   Normal  100 
Sex   
   Women 3966 71 
   Men 4570 112 
   Unknown 687 17 
Age (y)   
  Median (interquartile range) 57 (45-66) 61 (56-63) 
  Unknown age (n) 5126 64 
Manufacturer    
   Siemens 4719 62 
   GE 3406 68 
   Philips 528 24 
   Toshiba 2 28 
   Unknown or other 568 18 
Slice thickness (mm)   
   ≤ 1.5 8674 56 
   1.5-3.0 395 124 
   > 3.0 154 20 
Reconstruction kernel   
   Soft 8393 119 
   Hard 179 81 
   Unknown 651 0 
 
 
Note.— Both data from the training and testing sets were derived from multiple clinical sites in Europe, 
Canada, and the United States.   
Table 2. Properties of Training and Testing Data used for the Segmentation of Abnormalities Associated 
with COVID-19 
 
 
Parameter 
Training 
dataset 
Testing 
dataset 
Dataset composition   
   Total 901 200 
   COVID-19 431 100 
   Viral Pneumonia 174 0 
   Interstitial Lung Disease 296 0 
   Normal 0 100 
Sex   
   Women 247 71 
   Men 300 112 
   Unknown 354 17 
Age (y)   
   Median (interquartile range) 60 (51-68) 61 (56-63) 
   Unknown 533 64 
Manufacturer    
   Siemens 485 62 
   GE 201 68 
   Philips 34 24 
   Toshiba 17 28 
   Unknown or other 164 18 
Slice thickness (mm)   
   ≤ 1.5 533 56 
   1.5-3.0 285 124 
   > 3.0 83 20 
Reconstruction kernel   
   Soft 111 119 
   Hard 489 81 
   Unknown 301 0 
 
 
Note.— Both data from the training and testing sets were derived from multiple clinical sites in Europe, 
Canada, and the United States. 
 
 
 
Table 3. Pearson’s Correlation Coefficient Between Predicted Disease Severity Measures and Measures 
Derived from Ground Truth for 100 COVID-19 Positive and 100 Control Test Cases 
 
 
 
 
Note.— COVID-10 = coronavirus disease 2019, LHOS = lung high opacity score, LSS = lung severity score, 
PHO = percentage of high opacity, PO = percentage of opacity 
 
 
 
 
Table 4. Model Fitting Parameters for Predicted Disease Severity Measures and Measures Derived from 
Ground Truth for 100 COVID-19 Positive only 
 
 
 
 
 
 
 
Note.— PHO = percentage of high opacity, PO = percentage of opacity 
 
 
 
Chi-squared contingency test 
(COVID-19 and Control) 
Pearson’s Correlation 
(COVID-19 and Control) 
Pearson’s Correlation 
(COVID-19 only) 
Kendall’s Rank 
Correlation 
(COVID-19 only) 
Metric Chi2 P value Coefficient P value Coefficient P value Tau P value 
PO 2.11 0.72 0.95 < .001 0.92 < .001 0.77 < .001 
PHO 1.00 0.60 0.98 < .001 0.97 < .001 0.86 < .001 
LSS 23.50 0.2 0.96 < .001 0.91 < .001 0.83 <.001 
LHOS 2.21 0.95 0.96 < .001 0.9 <.001 0.83 <.001 
  Model Fit 
Metric R2 Mean error Intercept 
(estimate, confidence interval) 
Slope 
(estimate, confidence interval) 
PO 0.854 3.5% 0.033, [0.013, 0.054] 0.839, [0.769, 0.908] 
PHO 0.948 1.9% 0.004, [0.002, 0.007] 0.805, [0.768, 0.843] 
FIGURES 
Figure 1. The system takes as input a non-contrasted chest CT and segments the lesions, lungs, and lobes 
into three dimensions. It outputs two combined measures of the severity of lung and lobe involvement, 
quantifying both the extent of COVID-19 abnormalities and presence of high opacities. The first measure 
(Percentage of Opacity, Percentage of High Opacity) or (PO, PHO) is global, while the second measure 
consists of  (Lung Severity Score, Lung High Opacity Score) or (LSS, LHOS) is lobe-wise (see section COVID-
19 Severity Metrics).  GGO = ground-glass opacities 
 
Figure 2. The training and testing set composition in terms of country of origin and lung pathology. ILD = 
interstitial lung disease  
Figure 3. Overview of the deep learning system implemented in this work. LHOS = lung high opacity 
score, LSS = lung severity score, PHO = percentage of high opacity, PO = percentage of opacity 
Figure 4. Scatter plots for the four metrics computed on 100 COVID-19 cases and 100 controls. (a) 
Ground truth vs. predicted percentage of opacity (PO). (b) Ground truth vs. predicted lung severity score 
(LSS). (c) Ground truth vs. predicted percentage of high opacity (PHO). (d) Ground Truth vs. predicted 
lung high opacity score (LHOS). Note that a small jitter (0.2%) is added for the purpose of visualization to 
represent overlapping points.  
Figure 5. Combined severity measures of (a) (Percentage of Opacity, Percentage of High Opacity) or (PO, 
PHO ) and (b) (Lung Severity Score, Lung High Opacity Score) or (LSS, LHOS) computed on 100 COVID-19 
cases and 100 normal control CT scans. PO indicates the extent of opacity and PHO indicates the extent 
of the abnormality that has a high opacity, corresponding to consolidation regions. (a) The diagonal line 
indicates PO and PHO are equal (ie the abnormalities have 100% consolidation). The closer a marker is 
to the diagonal, the higher the relative percentage of consolidation in that . (b) The diagonal indicates 
that all the lobes that are affected have a high percentage of consolidation as well. The points below the 
diagonal indicate that some of the lobes affected do not have as severe consolidation as the others. (see 
section COVID-19 Severity Metrics). Note that a small jitter (0.2%) is added for the purpose of 
visualization to represent overlapping points.   
Figure 6. Visualization of segmented abnormality regions. (a) Combined severity measures (PO, PHO) 
and (LSS, LHOS) computed for six successful cases. (b) Shows the same result side by side for 
abnormality segmentation, and just the high opacity segmentation. (c) Shows some of the outliers of the 
system. 
 
APPENDIX E1 
Annotation Details 
ITK-Snap was used for ground truth annotation of lung, lobe, and abnormality segmentation task. The 
window level and width are adjusted to 425 and 1500. The annotation task was performed by a team of 
25 expert medical annotation engineers with a median of 2.25 years of experience of annotating 
medical imaging studies (range: 1-3.5 years). The tasks were performed under the supervision of 3 
board-certified radiologists with 2, 5, and 24 years of experience. Every dataset was initially annotated 
by our annotators and later reviewed and corrected by a radiologist for any areas missed or to be 
removed. 
The lung lobe masks were initialized by a pre-trained segmentation model. The mask follows the lung 
boundary against the mediastinum and soft tissue chest wall. The lung lobe segmentation mask covers 
the lung parenchyma from the division of the primary to secondary bronchus onwards. The mask 
adjusted to lung parenchymal window for best visualization of opacities includes any areas of 
consolidation, collapse and other abnormalities. The lung lobe annotation was performed by separating 
the whole lung into three right lobes and two left lobes at the fissure boundaries with different mask 
labels.  A subset of the training dataset of 8087 chest CT was annotated previously as a part of the 
COPDgene study (14).    
For the ground truth of the abnormality a single label mask included all areas of ground glass opacity 
and consolidation within both lung fields however pleural effusion was excluded in the mask. For crazy 
paving pattern the mask excluded normal areas of the lung with precision contouring of the mask. 
The average time for annotation and review of the lung and lobe masks is 2 hours.  
Abnormality Segmentation Network Architecture 
The training images are firstly resampled to the resolution 1 × 1 × 3mm. The image intensity is clipped 
using the standard lung window with the width 1500 HU and level −600 HU before being normalized to 
[0,1]. We use the predicted lung masks described in Sec. II-B to compute the geometric center of the 
lungs and then crop the image with a fixed bounding box of size 384 × 384 × 384. For data 
augmentation, we perturb the image intensity within a random interval [−20,20] and then flip the image 
in one of the three dimensions by 50% chance. The tensor 3D dimensions are kept in z-y-x order 
throughout training and inference. 
We use a UNet (17) resembling architecture with convolutional blocks containing either 1 × 3 × 3 or 3 × 
3 × 3 CNN kernels to deal with the anisotropic image resolutions. The network architecture is illustrated 
in Figure 3. The 3D input tensor is first fed into a 3D 1 × 3 × 3 convolutional layer followed by batch 
normalization and LeakyReLU. The features are then propagated to 5 DenseNet blocks (26). For the first 
two DenseNet blocks, the features are downsampled by a 1 × 2 × 2 convolution with a stride of 1 × 2 × 
2. These anisotropic downsampling kernels are designed to preserve the inter-slice resolution of the 
input tensors. The last 3 DenseNet blocks have isotropic downsampling kernels with the stride of 2 × 2 × 
2. The input to each decoder block is obtained by concatenating the encoder output features with the 
same resolution and the features upsampled from the previous decoder. The upsampling kernels are 
built with transpose convolutional kernels with the sizes and strides same to the corresponding 
DenseNet blocks. The final network output is derived by projecting the feature maps to 2 feature 
channels and being activated by the softmax activation. The network parameters are randomly 
initialized. 
We use the Jaccard index as the training loss function. The loss function L(p, y) between the probability 
prediction tensor p and the ground truth tensor y is only computed within the precomputed lung 
segmentation as 
  
Where  is the smoothing factor and · represents the tensor inner product operator. The loss 
function is optimized using Adabound (27) with an initial learning rate 0.001. The final model used for 
testing is selected using a validation set with 10 % of the training set patients that is randomly sampled. 
The training and testing pipeline were implemented using Pytorch.  
 
